Last Updated: November 16, 2026

Fecal microbiota, live-jslm - Biologic Drug Details

« Back to Dashboard


Summary for fecal microbiota, live-jslm
Tradenames:1
High Confidence Patents:6
Applicants:1
BLAs:1
Suppliers: see list1
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. DrugPatentWatch analysis and brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for fecal microbiota, live-jslm Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for fecal microbiota, live-jslm Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Ferring Pharmaceuticals Inc. REBYOTA fecal microbiota, live-jslm Suspension 125739 12,036,250 2043-03-30 DrugPatentWatch analysis and company disclosures
Ferring Pharmaceuticals Inc. REBYOTA fecal microbiota, live-jslm Suspension 125739 12,083,150 2042-12-07 DrugPatentWatch analysis and company disclosures
Ferring Pharmaceuticals Inc. REBYOTA fecal microbiota, live-jslm Suspension 125739 12,102,655 2044-04-10 DrugPatentWatch analysis and company disclosures
Ferring Pharmaceuticals Inc. REBYOTA fecal microbiota, live-jslm Suspension 125739 9,433,651 2034-06-30 DrugPatentWatch analysis and company disclosures
Ferring Pharmaceuticals Inc. REBYOTA fecal microbiota, live-jslm Suspension 125739 9,675,648 2034-06-04 DrugPatentWatch analysis and company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for fecal microbiota, live-jslm Derived from Patent Text Search

These patents were obtained by searching patent claims

Fecal Microbiota, Live-jslm Market Dynamics, Patent Position, and Financial Trajectory

Last updated: August 27, 2026

Fecal microbiota, live-jslm, marketed as Rebyota by Ferring Pharmaceuticals, is the first FDA-approved fecal microbiota product. The live biotherapeutic is administered rectally to reduce recurrent Clostridioides difficile infection after antibacterial treatment in adults. Its commercial trajectory depends on three factors: conversion of fecal microbiota transplantation from a procedure into a reimbursed drug category, competition from the oral product Vowst, and the ability to secure recurring payer and provider coverage.

Rebyota has regulatory differentiation but limited exclusivity visibility. It is licensed under a biologics license application rather than approved as a conventional small-molecule drug. The product does not have the same Orange Book patent-listing profile as a tablet or capsule. FDA biologic exclusivity, manufacturing know-how, donor-screening controls, and clinical evidence are more important barriers than publicly visible composition-of-matter patents.

What is fecal microbiota, live-jslm and how does Rebyota work?

Fecal microbiota, live-jslm is a standardized suspension of live microorganisms derived from human stool donations. The product is intended to restore intestinal microbiota after antibacterial treatment for recurrent C. difficile infection.

Rebyota is supplied as a single rectally administered dose. The FDA-approved indication covers adults following antibiotic treatment for recurrent C. difficile infection. It is not approved to treat active C. difficile infection or to replace antibacterial therapy.

Key product facts

Attribute Rebyota
Active product name Fecal microbiota, live-jslm
Brand Rebyota
Developer and marketer Ferring Pharmaceuticals
FDA approval November 30, 2022
Regulatory pathway Biologics license application, BLA 125739
Dosage form Rectal suspension
Administration Single rectal dose
Approved population Adults after antibiotic treatment for recurrent C. difficile infection
Primary commercial competitor Vowst, fecal microbiota spores, live-brpk
Initial list-price range Approximately $9,000 per treatment, subject to payer and contracting terms

In the pivotal PUNCH CD3 study, Rebyota reduced recurrence compared with placebo. The FDA label reported treatment success at eight weeks of 70.6% for Rebyota versus 57.5% for placebo. The product’s clinical value is concentrated in patients with multiple recurrences, where further antibiotic cycles carry substantial clinical and economic costs.[1]

How large is the market for Rebyota and fecal microbiota products?

The addressable market is smaller than the total C. difficile disease market because Rebyota is indicated only after antibiotic treatment for recurrent disease. The commercial pool includes adults with recurrent infections who are medically suitable for microbiota restoration and whose payers authorize a high-cost biologic or live biotherapeutic.

C. difficile generates a large number of U.S. infections annually, but the relevant recurrent-disease segment is narrower. Commercial expansion therefore depends more on treatment penetration than on broad epidemiological growth.

Market drivers

Rebyota benefits from several structural factors:

  1. Recurrent C. difficile creates a clear need for recurrence prevention.
  2. Hospitals and infectious-disease specialists already recognize microbiota transplantation as a clinical concept.
  3. A licensed product can reduce reliance on locally sourced stool and procedure-based transplantation.
  4. Rebyota can be administered without colonoscopy.
  5. Payers may view recurrence prevention as less expensive than repeated hospitalization, emergency care, and antibiotic treatment.

Market constraints

Adoption is limited by:

  • Uneven payer coverage and prior authorization requirements.
  • Provider uncertainty over whether to use Rebyota, Vowst, or conventional fecal microbiota transplantation.
  • Site-of-care logistics for rectal administration.
  • The need to identify eligible patients after antibiotic completion.
  • Product handling, cold-chain requirements, and qualified administration sites.
  • Competition from oral Vowst, which may be easier for some patients to receive.
  • Low awareness outside gastroenterology, infectious disease, and hospital settings.

How does Rebyota compare with Vowst?

Rebyota and Vowst target the same broad treatment segment but use different delivery systems. Rebyota is a rectal suspension, while Vowst is an oral capsule product based on purified microbiota spores.

Product Rebyota Vowst
Active ingredient Fecal microbiota, live-jslm Fecal microbiota spores, live-brpk
Sponsor Ferring Pharmaceuticals Seres Therapeutics, with commercial involvement from Nestlé Health Science
FDA approval 2022 2023
Administration Single rectal dose Four capsules daily for three days
Primary differentiator Single-dose rectal delivery and earlier market entry Oral administration and capsule convenience
Reported pivotal endpoint 70.6% treatment success at eight weeks versus 57.5% placebo 88% recurrence-free rate at eight weeks versus 60% placebo
Principal barrier Administration setting and reimbursement Oral adherence, cost, and access

The products are not clinically interchangeable on the basis of cross-trial comparisons. Their pivotal studies used different designs, populations, endpoints, and placebo regimens. Vowst’s oral format creates a material competitive threat because it may fit specialty-pharmacy distribution and home administration more easily.[2]

Rebyota retains advantages in being first to market and in having an established rectal formulation. Vowst has a stronger convenience proposition. Prescriber choice is likely to depend on patient preference, payer policy, institutional protocols, and whether the treatment is delivered in a hospital, physician office, or specialty-pharmacy channel.

What is the FDA regulatory and exclusivity status of Rebyota?

Rebyota is an FDA-licensed biological product. Its approval under BLA 125739 distinguishes it from conventional prescription drugs approved through an NDA or ANDA pathway.

The product’s regulatory position includes:

  • FDA approval on November 30, 2022.
  • Indication for prevention of recurrent C. difficile infection in adults after antibacterial treatment.
  • A boxed-warning-free label, although the FDA label includes warnings concerning transmission of infectious agents and the potential for adverse events.
  • Donor screening and testing requirements.
  • Manufacturing controls that are central to product quality.
  • Biologic exclusivity under the Biologics Price Competition and Innovation Act framework, subject to the product’s statutory classification and FDA listing.

For a licensed reference biologic approved in 2022, the statutory 12-year reference-product exclusivity framework points to a nominal endpoint in 2034. The four-year period during which a biosimilar application generally cannot be submitted would nominally end in 2026. FDA implementation and product-specific determinations remain important because fecal microbiota products have unusual biological and manufacturing characteristics.[3]

Does Rebyota have Orange Book patents?

Rebyota is not a conventional small-molecule drug with a standard Orange Book patent strategy. The FDA Orange Book principally lists approved drug products and patent information associated with NDA products. Rebyota’s core protection is more likely to arise from:

  • BLA exclusivity.
  • Manufacturing and purification processes.
  • Donor-screening and pathogen-control systems.
  • Formulation and stability controls.
  • Clinical and analytical data.
  • Trade secrets involving donor material, microbial composition, testing, and release criteria.
  • Regulatory complexity associated with producing a consistent live microbiota product.

The absence of a conventional Orange Book patent listing does not mean that competing products can freely copy Rebyota. A biosimilar or other biologic competitor would need to meet FDA requirements for quality, safety, potency, manufacturing consistency, and clinical comparability.

What patents protect fecal microbiota, live-jslm?

Publicly visible patent protection for Rebyota is less transparent than for a branded small molecule. The principal commercial barrier is not a single easily identified active-ingredient patent. Human-derived microbiota products raise difficult patent-scope questions because claims may focus on preparation methods, microbial compositions, donor selection, administration, or use in preventing recurrence.

Relevant patent categories include:

Manufacturing and donor-control patents

These may cover donor qualification, stool collection, pathogen testing, processing, filtration, concentration, storage, and release testing. The commercial value of this layer can exceed the value of broad composition claims because reproducibility is difficult to achieve.

Formulation and stability patents

Potential claim areas include suspension vehicles, cryopreservation, container systems, microbial viability, thawing, and administration protocols. A formulation patent may be commercially relevant even if it does not cover every fecal microbiota product.

Method-of-use patents

Method claims may cover administration after antibacterial treatment, prevention of recurrent C. difficile infection, dosing schedules, or use in defined patient populations. Their enforceability depends on claim language, prescribing behavior, labeling, and the extent to which the approved indication is practiced.

Trade-secret protection

Ferring’s donor network, manufacturing procedures, microbial characterization, and release criteria can operate as trade-secret assets. These protections do not appear in the same way as an issued patent and are difficult for competitors to evaluate from public databases.

Are there Paragraph IV challenges or generic entry risks?

There is no standard ANDA generic-entry pathway for Rebyota because it is a biologic licensed under a BLA. A conventional Paragraph IV challenge is therefore not the primary regulatory threat.

The more relevant entry routes are:

  • A biosimilar application under the Public Health Service Act.
  • A separately developed biologic or live biotherapeutic product.
  • An alternative fecal microbiota product with a different formulation or route of administration.
  • Conventional fecal microbiota transplantation offered under applicable FDA enforcement policies.
  • New microbiome-based products that avoid direct biosimilar classification.

No publicly reported Rebyota Paragraph IV litigation is a central market event. The competitive litigation risk is more likely to involve patents covering manufacturing, microbiota compositions, or methods of use than an ANDA case against a listed small-molecule product.

When does Rebyota lose exclusivity?

Protection layer Relevant timing
FDA approval November 30, 2022
Four-year biologic application submission bar Nominally November 30, 2026
Twelve-year reference-biologic exclusivity Nominally November 30, 2034
Patent term Depends on issued claims, filing dates, and any patent-term adjustment or extension
Trade secrets No fixed statutory expiration while secrecy is maintained
Regulatory know-how No fixed statutory expiration, but advantage can erode through competitor development

The practical market-entry date may occur before 2034 if a competing product does not rely on the same reference product or if FDA classifies the entrant outside the biosimilar pathway. As a result, the commercial moat is stronger against direct copying than against alternative microbiome technologies.

What is the financial trajectory for Rebyota?

Ferring is privately held and does not provide the same quarterly product-level revenue disclosure as a public pharmaceutical company. Public filings and company communications do not establish a consistently reported standalone Rebyota revenue series. The financial trajectory must therefore be assessed through market access, prescription volume, pricing, and competitive share rather than verified quarterly sales.

Commercial trajectory

2022: Regulatory launch

FDA approval created a new reimbursable product category but did not immediately solve distribution and coverage challenges. Initial commercialization focused on specialist centers, hospital systems, and patients with multiple recurrences.

2023: Category expansion

The launch of Vowst expanded awareness of microbiota restoration while intensifying product comparison. This period likely increased total category visibility but also divided prescriber and payer attention.

2024 onward: Reimbursement and channel competition

The market’s next phase depends on whether products move from specialist use into routine post-antibiotic protocols. Rebyota’s revenue growth is likely to be driven by:

  • More patients identified before discharge or antibiotic completion.
  • National payer coverage.
  • Hospital order sets and infectious-disease protocols.
  • Contracting with specialty pharmacies and infusion or procedure networks.
  • Reduced administrative friction.
  • Clear comparative positioning against Vowst.

A $9,000 treatment price creates substantial gross-revenue potential even at modest penetration. For example, 5,000 treated patients would represent approximately $45 million in gross product value before rebates, distribution discounts, and other deductions. At 25,000 patients, gross value would approach $225 million. These are revenue-sensitivity calculations, not reported Rebyota sales.

Net revenue will be lower than list-price multiplication because payer rebates, chargebacks, distribution fees, patient assistance, and site-of-care economics affect realized price. Ferring’s private ownership limits external visibility into those deductions.

What manufacturing and intellectual-property barriers affect Rebyota?

Manufacturing is a meaningful barrier to entry because fecal microbiota is a complex biological material rather than a single chemically defined molecule. Critical controls include:

  • Donor recruitment and retention.
  • Repeated donor testing for pathogens.
  • Screening for emerging infectious risks.
  • Standardized collection and transport.
  • Microbial viability after processing and storage.
  • Batch consistency.
  • Testing for contaminants and antimicrobial resistance markers.
  • Traceability from donor material to finished dose.

These controls raise cost and operational complexity. They also limit the number of companies capable of producing a commercially consistent product at scale.

The main weakness is that biological complexity can also complicate differentiation. If clinical outcomes are driven by a broad restoration of microbiota function rather than a narrowly defined molecular mechanism, patent claims may be difficult to make broad and durable.

What litigation and settlement risks affect Rebyota?

There is no major publicly reported settlement or patent-litigation event that currently defines Rebyota’s market position. The more material legal risks are prospective:

  1. Patent disputes over donor-derived compositions or processing methods.
  2. Biosimilar or alternative-biologic challenges after the statutory exclusivity period.
  3. Product-liability claims involving pathogen transmission.
  4. Contract disputes involving stool donors, collection networks, or distributors.
  5. Regulatory disputes over manufacturing changes and comparability.
  6. Coverage litigation or reimbursement disputes involving payer classification.

The FDA label specifically addresses the risk of transmitting infectious agents. That risk makes pharmacovigilance, donor screening, and manufacturing documentation important commercial assets as well as regulatory obligations.[1]

How does Rebyota compare with conventional fecal microbiota transplantation?

Rebyota offers a regulated, standardized product alternative to conventional fecal microbiota transplantation. Conventional transplantation may be delivered through colonoscopy, enema, nasogastric tube, or other procedures under FDA enforcement discretion and institutional protocols.

Factor Rebyota Conventional transplantation
Regulatory status FDA-approved product Procedure-based approach subject to FDA enforcement policy
Standardization Manufacturer-controlled Variable by donor, site, and protocol
Administration Single rectal dose Procedure-dependent
Commercial model Product reimbursement Procedure and facility reimbursement
Supply Centralized donor network Local or stool-bank dependent
Evidence package Product-specific clinical trials Heterogeneous literature
Main advantage Standardized and scalable Potentially lower product cost and local flexibility
Main risk Price and access Variability and infectious-risk controls

Rebyota’s commercial opportunity increases when clinicians and payers value standardization, traceability, and FDA approval. Its competitive pressure increases when institutions can provide conventional transplantation at lower cost.

Key Takeaways

  • Fecal microbiota, live-jslm, marketed as Rebyota, is the first FDA-approved fecal microbiota product.
  • Ferring’s product is approved for preventing recurrent C. difficile infection in adults after antibacterial treatment.
  • Rebyota’s nominal biologic exclusivity framework extends into 2034, while a conventional Paragraph IV generic challenge is not the relevant entry pathway.
  • Orange Book patent visibility is limited because Rebyota is a BLA product rather than a conventional NDA drug.
  • Manufacturing, donor screening, pathogen control, formulation, and clinical data are central barriers to competition.
  • Vowst is the main commercial competitor and has an oral dosing advantage.
  • Ferring does not publicly report a detailed standalone Rebyota revenue series, so financial assessment depends on adoption and reimbursement indicators.
  • The main market risk is slow payer and provider adoption, not immediate generic substitution.
  • The main long-term risk is alternative microbiome technology that reaches the market outside a direct biosimilar pathway.

FAQs About Fecal Microbiota, Live-jslm

Is Rebyota a biologic drug?

Yes. Rebyota is licensed by FDA under BLA 125739 as a biological product. Its regulatory and exclusivity framework differs from that of conventional small-molecule drugs.

Is Rebyota the same as a fecal microbiota transplant?

No. Rebyota is a manufactured, FDA-approved fecal microbiota product. Conventional fecal microbiota transplantation is a procedure-based intervention that may be prepared and administered under different regulatory conditions.

Can a pharmacy substitute Vowst for Rebyota?

No automatic generic substitution should be assumed. Rebyota and Vowst are different FDA-approved products with different active-product descriptions, routes of administration, clinical programs, and labeling.

What is the biggest commercial threat to Rebyota?

The main threat is not a traditional generic. It is competition from Vowst, conventional transplantation, and future microbiome products with oral or otherwise simplified administration.

Does Rebyota have biosimilar competition?

No marketed biosimilar competition has been established. Future competition could arise through the biosimilar pathway or through independently developed microbiome products that do not rely directly on Rebyota as the reference product.

References

  1. U.S. Food and Drug Administration. (2022). Rebyota (fecal microbiota, live-jslm) prescribing information.
  2. U.S. Food and Drug Administration. (2023). Vowst (fecal microbiota spores, live-brpk) prescribing information.
  3. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
  4. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
  5. U.S. Congress. (2010). Patient Protection and Affordable Care Act, Biologics Price Competition and Innovation Act provisions.
  6. Ferring Pharmaceuticals. (2022). Ferring receives FDA approval for Rebyota, the first microbiota-based live biotherapeutic product in the United States.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.